Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Blood

• Publication date

  2010-10-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2010-02-267708PMID 20581312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analytical validation of a high-sensitivity cardiac troponin T assay.

  2010cited by this paper
• Sensitive troponin I assay in early diagnosis of acute myocardial infarction.

  2009cited by this paper
• A sensitive cardiac troponin T assay in stable coronary artery disease.

  2009cited by this paper
• Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light‐chain amyloidosis

  2009cited by this paper
• Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays.

  2009cited by this paper
• Early diagnosis of myocardial infarction with sensitive cardiac troponin assays.

  2009cited by this paper
• Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring.

  2009cited by this paper
• Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia.

  2008cited by this paper
• Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

  2008cited by this paper
• Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

  2008cited by this paper
• An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis

  2007cited by this paper
• Suspected cardiac amyloidosis: Endomyocardial biopsy remains the diagnostic gold‐standard

  2007cited by this paper
• Universal definition of myocardial infarction.

  2007cited by this paper
• Universal definition of myocardial infarction.

  2007cited by this paper
• Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure

  2007cited by this paper
• Non‐invasive predictors of survival in cardiac amyloidosis

  2007cited by this paper
• Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis.

  2007cited by this paper
• Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function.

  2006cited by this paper
• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

  2005cited by this paper
• High‐dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

  2004cited by this paper
• Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

  2004cited by this paper
• Noninvasive diagnosis of biopsy-proven cardiac amyloidosis.

  2004cited by this paper
• Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

  2004cited by this paper
• Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial.

  2003cited by this paper
• Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

  2003cited by this paper
• Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis

  2003cited by this paper
• New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function.

  2002cited by this paper
• Prognostic Significance of Ultrasound Myocardial Tissue Characterization in Patients With Cardiac Amyloidosis

  2002cited by this paper
• Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.

  2001cited by this paper
• Holter Monitoring in AL Amyloidosis: Prognostic Implications

  2001cited by this paper
• It's time for a change to a troponin standard.

  2000cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

  1999cited by this paper
• Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes.

  1997cited by this paper
• Diagnostic Efficiency of Troponin T Measurements in Acute Myocardial Infarction

  1991cited by this paper
• Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.

  1986cited by this paper
• Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

  1986cited by this paper
• Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival.

  1985cited by this paper
• Amyloidosis (AL). Clinical and laboratory features in 229 cases.

  1983cited by this paper
• Amyloidosis (AL). Clinical and laboratory features in 229 cases.

  1983cited by this paper
• Declaration of Helsinki. Recommendations guiding doctors in clinical research. Adopted by the World Medical Association in 1964.

  1967cited by this paper

• A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.

  2025cites this paper
• Serum Biomarkers

  2025cites this paper
• Up-to-date review on heart transplantation and other advanced heart failure therapies in cardiac amyloidosis patients.

  2025cites this paper
• Coronary Artery Disease in Cardiac Amyloidosis: Prevalence, Clinical Relevance, and Cardiac Magnetic Resonance Imaging Features

  2025cites this paper
• Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus Statement.

  2025cites this paper
• Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era

  2025cites this paper
• High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis.

  2024cites this paper
• A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots

  2024cites this paper
• Clinical Interpretation of Serum Troponin in the Era of High-Sensitivity Testing

  2024cites this paper
• Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study

  2024cites this paper
• Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis

  2023cites this paper
• Association between the TAPSE to PASP ratio and short-term outcome in patients with light-chain cardiac amyloidosis.

  2023cites this paper
• Association of high-sensitivity troponin T with outcomes in asymptomatic non-severe aortic stenosis: a post-hoc substudy of the SEAS trial

  2023cites this paper
• Clinical characteristics and prognostic value of renal immune complex deposition in patients with light chain amyloidosis

  2022cites this paper
• Red flags for the diagnosis of cardiac amyloidosis: simple suggestions to raise suspicion and achieve earlier diagnosis

  2022cites this paper
• Amiloidosis AL: conceptos actuales

  2022cites this paper
• Amyloid Cardiomyopathy in Older Adults

  2022cites this paper
• Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

  2021cites this paper
• Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis

  2021cites this paper
• Biomarkers in AL Amyloidosis

  2021cites this paper
• Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters

  2021cites this paper
• Use of biomarkers to diagnose and manage cardiac amyloidosis

  2021cites this paper
• Bone Tracers for the Diagnosis of Cardiac Amyloidosis

  2021cites this paper
• Prognosis and Staging of AL Amyloidosis

  2020cites this paper
• Utility of Biomarkers in Cardiac Amyloidosis.

  2020cites this paper
• Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings

  2020influential citation
• Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction.

  2020cites this paper
• Practice pattern of use of high sensitivity troponin in the outpatient settings

  2020cites this paper
• Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.

  2019cites this paper
• Use of Cardiac Troponin Testing in the Outpatient Setting

  2019cites this paper
• Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

  2019cites this paper
• Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

  2019cites this paper
• Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia

  2019cites this paper
• Cardiovascular magnetic resonance imaging for amyloidosis: The state-of-the-art.

  2019cites this paper
• [Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].

  2019cites this paper
• Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis

  2019cites this paper
• A risk stratification for systemic immunoglobulin light‐chain amyloidosis with renal involvement

  2019cites this paper
• Systemic immunoglobulin light chain amyloidosis

  2018cites this paper
• Current and future circulating biomarkers for cardiac amyloidosis

  2018cites this paper
• Cardiac amyloidosis: from clinical suspicion to morphological diagnosis.

  2018cites this paper
• Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis

  2018cites this paper
• Management of the elderly patient with AL amyloidosis.

  2018cites this paper
• Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines

  2018cites this paper
• Predictors of survival stratification in patients with wild-type cardiac amyloidosis

  2018cites this paper
• From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

  2017cites this paper
• Kidney Involvement in Light Chain Amyloidosis

  2017influential citation
• Amyloid cardiomyopathy.

  2017cites this paper
• Prognostic significance of interventricular septal thickness in patients with AL amyloidosis.

  2017cites this paper
• Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis

  2017cites this paper
• An unusual case of chronic lymphocytic leukemia, multiple myeloma and cardiac amyloidosis

  2017cites this paper
• New and developing therapies for AL amyloidosis

  2017cites this paper
• Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up

  2017cites this paper
• Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)

  2017cites this paper
• [What should we know about cardiac amyloidosis? From clinical signs to treatment].

  2017cites this paper
• D-Dimer: A Novel Predictor of Survival in Patients with Cardiac Light- Chain Amyloidosis

  2017cites this paper
• Short‐ and long‐term outcomes of AL amyloidosis patients admitted into intensive care units

  2016cites this paper
• Systemic amyloidosis.

  2016cites this paper
• Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis

  2016cites this paper
• European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.

  2016cites this paper
• Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis.

  2016cites this paper
• Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

  2016cites this paper
• What is new in diagnosis and management of light chain amyloidosis?

  2016cites this paper
• Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*

  2016cites this paper
• Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.

  2016cites this paper
• Solid- and Solution-State Nuclear Magnetic Resonance Spectroscopic Analysis of Amyloidogenic Immunoglobulin Light Chains and their Interactions with Epigallocatechin Gallate

  2016cites this paper
• Systemic amyloidosis by Cardiovascular Magnetic Resonance

  2016cites this paper
• Ecocardiografía speckle tracking (rastreo de marcas) tridimensional en la amiloidosis cardiaca de cadenas ligeras: estudio de los parámetros de mecánica miocárdica ventricular izquierda y derecha

  2015cites this paper
• Three-dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters.

  2015cites this paper
• Current applications of biomarkers in cardiomyopathies

  2015cites this paper
• Pericardial Effusion and Multiple Organ Involvement Are Independent Predictors of Mortality in Patients with Systemic Light Chain Amyloidosis.

  2015cites this paper
• Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis

  2015cites this paper
• Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study

  2015cites this paper
• Natural history and therapy of AL cardiac amyloidosis

  2015cites this paper
• Novel strategies for the diagnosis and treatment of cardiac amyloidosis

  2015cites this paper
• Soluble suppression of tumorigenicity 2 (sST2), but not galactin‐3, adds to prognostication in patients with systemic AL amyloidosis independent of NT‐proBNP and troponin T

  2015cites this paper
• Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

  2015cites this paper
• Systemic Amyloidosis – Insights by Cardiovascular Magnetic Resonance

  2015cites this paper
• Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)

  2014cites this paper
• High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis

  2014cites this paper
• A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

  2014cites this paper
• Reprint of: Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.

  2014cites this paper
• Noninvasive risk stratification of patients with transthyretin amyloidosis.

  2014cites this paper
• Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.

  2014cites this paper
• Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis

  2014cites this paper
• Biomarkers in Cardiology – Part 1 – In Heart Failure and Specific Cardiomyopathies

  2014cites this paper
• Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis

  2014cites this paper
• Predictive Value of Assessing Diastolic Strain Rate on Survival in Cardiac Amyloidosis Patients with Preserved Ejection Fraction

  2014cites this paper
• Cardiac amyloidosis: the heart of the matter

  2013cites this paper
• Systemic amyloidoses: what an internist should know.

  2013cites this paper
• A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

  2013cites this paper
• High sensitivity troponin in cardiovascular disease. Is there more than a marker of myocardial death?

  2013cites this paper
• Cardiac Amyloidosis: Typing, Diagnosis, Prognosis and Management

  2013cites this paper
• Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis

  2013cites this paper
• Systemic light chain amyloidosis: an update for treating physicians.

  2013cites this paper
• Chapter 3 Cardiac Amyloidosis : Typing , Diagnosis , Prognosis and Management

  2013cites this paper
• Cardiac amyloidosis: updates in diagnosis and management.

  2013cites this paper
• The importance of selected laboratory parameters for the diagnostics, stratification and monitoring of AL amyloidosis patients

  2013cites this paper
• What do I need to know about immunoglobulin light chain (AL) amyloidosis?

  2012cites this paper
• Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

  2012cites this paper
• Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease

  2012cites this paper